Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 21.688 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: arginine; hyprolose; colloidal anhydrous silica; lactose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; sodium carbonate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - lorstat is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,lorstat is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see section 5.1 pharmacodynamic properties, clinical trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - atorvastatin calcium trihydrate, quantity: 10.844 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; microcrystalline cellulose; lactose; sodium carbonate; arginine; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - lorstat is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,lorstat is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (section 5.1 pharmacodynamic properties, clinical trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fosinopril sodium; hydrochlorothiazide -

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.micardisplus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.micardisplus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on micardisplus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - difelikefalin acetate, quantity: 55 microgram (equivalent: difelikefalin, qty 50 microgram) - injection, solution - excipient ingredients: sodium chloride; sodium acetate trihydrate; acetic acid; water for injections - korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - hydrochlorothiazide; losartan potassium - tablets - losartan potassium 50 mg; hydrochlorothiazide 12.50 mg - losartan and diuretics - losartan and diuretics - ocsaar plus is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. to reduce the risk of stroke in patients with hyperfension adn left ventricular hypertrophy.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 25 mg - tablet, multilayer - excipient ingredients: maize starch; sorbitol; sodium hydroxide; iron oxide yellow; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; sodium starch glycollate type a; meglumine - micardis plus is indicated for the treatment of hypertension. treatment should not be intitiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - hydrochlorothiazide, quantity: 12.5 mg; eprosartan mesilate, quantity: 735.8 mg (equivalent: eprosartan, qty 600 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - teveten plus is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sodium hydroxide; sorbitol; microcrystalline cellulose; iron oxide red; maize starch; lactose monohydrate; povidone; sodium starch glycollate - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: povidone; sodium hydroxide; microcrystalline cellulose; lactose monohydrate; sorbitol; sodium starch glycollate; maize starch; meglumine; magnesium stearate; iron oxide red - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.